INNOCAN PHARMA Corp (INNPF) Stock

About INNOCAN PHARMA Corp

InnoCan Pharma Corporation is a pharmaceutical enterprise dedicated to innovating drug delivery systems by integrating cannabidiol (CBD) with diverse pharmaceutical ingredients. Its operations extend across the United States, Poland, France, and other international markets. The company actively pursues research and development into CBD-loaded exosomes for treating conditions like COVID-19, as well as advancing CBD-infused liposomes. InnoCan Pharma also commercializes a range of branded CBD-integrated pharmaceutical and topical treatment products, such as CBD eye serum, face oil, face cream, facial serum, sleeping mask, recovery lotion, and the Relief & Go spray. Established in 2018, the corporation is headquartered in Calgary, Canada.

INNOCAN PHARMA Corp is headquartered in CA.

INNOCAN PHARMA Corp (INNPF) stock trades at $1.60 with a market capitalization of $7.20M. The stock is valued at a negative price-to-earnings (P/E) ratio of -6.68, reflecting a net loss over the last twelve months, price-to-book of 1.90, price-to-sales of 0.39. Over the past 52 weeks the stock has ranged between $1.60 and $14.26, and currently trades 88.8% below its 52-week high.

On profitability, INNOCAN PHARMA Corp generates a return on equity (ROE) of -31.76% (negative, reflecting a net loss), return on capital employed of -28.28%, an operating margin of -10.00%, a net profit margin of -5.95%.

Official website: innocanpharma.com